Boston Scientific
BSX
Performance
About Boston Scientific
Boston Scientific is a global medical device company that develops and manufactures innovative medical solutions to improve health outcomes for patients worldwide. The company offers products and therapies across multiple medical specialties, including cardiovascular, electrophysiology, neuro-modulation, urology, gastroenterology, and cancer treatment, serving healthcare professionals and patients globally. Its focus spans diagnostic and therapeutic devices, implants, and related customer support and education initiatives aimed at advancing patient care and safety. Headquartered with a worldwide presence, Boston Scientific emphasizes corporate responsibility, professional education, and patient resources to support clinicians and caregivers.
Recent News
Culturally Tailored Meals Improve HF Outcomes in Navajo Residents
Boston Scientific's EKOS System Cuts Pulmonary Embolism Mortality by 61% in HI-PEITHO Trial
Boston Scientific Knew of Pacemaker Battery Problems for Years
PharmaShots Quarterly Outlook: The Forces Reshaping Biopharma in Q1 2026
AIP to Take Avanos Medical Private in $1.27 B Deal
Biotech’s Next Chapter: Asset-Centric Deals and Shifting Alpha at JPM 2026
Next Step in Recycling More Healthcare Plastics: Better Labeling
The Zacks Analyst Blog Highlights Apple, TotalEnergies, Boston Scientific and Good Times Restaurants
Charlotte Emerging as a Global Leader in Health Care Innovation and Med Tech
#58797
How to Invest in Healthcare's Powerful Growth
Where Purpose Meets Performance: Elutia Earns 2026 Great Place to Work Certification
LAA Closure Superior to Anticoagulation for Bleeding in AF
Hippocratic AI Builds in Life Sciences with Grove AI Buy
Boston Scientific to Acquire Penumbra for $14.5B
Lee Ainslie: Concentrating Capital in AI Leaders While Pruning Legacy Positions
WATCHMAN FLX Beats Blood Thinners in CHAMPION-AF Trial, Cutting Bleeding Risk by 45%
Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process
E2 Raises $80M to Market Thrombectomy Platform
Lee Ainslie Portfolio Analysis: Key Positions, AI Bets & Maverick Capital Strategy
Boston Scientific Receives FDA Clearance for the Asurys Fluid Management System
Bank of America Beats Profit Forecasts as Trading, Investment Banking Drive Growth
E2 Raises $80M to Advance Pulmonary Embolism Treatment
Stryker Enters Competitive IVL Space with Acquisition of Amplitude Vascular Systems